Published in Food and Drug Law Weekly, November 5th, 2004
These preclinical data reveal that both XL647 and XL999 have promise for the treatment of various forms of cancer through selective inhibition of RTKs.
Both compounds are spectrum selective kinase inhibitors that simultaneously target multiple kinases implicated in various forms of cancer. Both compounds are in phase I clinical trials.
"The data released at EORTC is preclinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.